Allergan profit beats estimates as Botox maker mulls Valeant bid

Allergan Inc., the target of an unsolicited takeover bid by Valeant Pharmaceuticals International Inc., reported profit that beat analyst estimates as sales of its Botox treatment increased. First-quarter earnings, excluding one-time items, of $1.18 a share were 5 cents higher than the average...



via L.A. Times - Science http://ift.tt/1j2MIZp